Careful QTc monitoring with fluoroquinolone-azole combinations

This small retrospective single center cohort found that 22% of patients on combination fluoroquinolone-azole drugs had clinically significant prolongation of their QT interval. Careful monitoring should be done for patients on this combination of drugs (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment